Humanized mouse model of Rasmussen’s encephalitis supports the immune-mediated hypothesis
暂无分享,去创建一个
G. Holmes | H. Goodkin | E. Haddad | L. Carmant | S. Desgent | D. Nguyen | J. Mytinger | M. Connolly | J. I. Alvarez | A. Prat | M. Langlois | Jorge I Alvarez | Hania Kebir | F. Fontaine | K. Béland | C. Bosoi | N. Sanon | Camille L. Pittet | David Hébert | Rose-Marie Rébillard | C. Cieuta-Walti | J. Alvarez | R. Rébillard | François Fontaine | Ciprian M. Bosoi | Sébastien Desgent
[1] D. Greiner,et al. Humanized Mouse Models of Clinical Disease. , 2017, Annual review of pathology.
[2] C. Larochelle,et al. Focal disturbances in the blood–brain barrier are associated with formation of neuroinflammatory lesions , 2015, Neurobiology of Disease.
[3] F. Jensen,et al. Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances , 2014, The Lancet Neurology.
[4] H. Oguni,et al. Immunomodulatory therapy versus surgery for Rasmussen syndrome in early childhood , 2013, Brain and Development.
[5] H. Wiendl,et al. Rasmussen encephalitis treated with natalizumab , 2013, Neurology.
[6] C. Elger,et al. Rasmussen encephalitis: Incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins , 2013, Epilepsia.
[7] D. Greiner,et al. Humanized mice for immune system investigation: progress, promise and challenges , 2012, Nature Reviews Immunology.
[8] E. Haddad,et al. Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/γc− mouse model , 2012, Bone Marrow Transplantation.
[9] M. Prinz,et al. Role of ninjurin‐1 in the migration of myeloid cells to central nervous system inflammatory lesions , 2011, Annals of neurology.
[10] J. Salmon,et al. Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2-/- IL-2Rγ-/- mice: a promising model for studying human disease. , 2011, Arthritis and rheumatism.
[11] J. Hunter,et al. Dual pathology in Rasmussen's encephalitis: A study of seven cases and review of the literature , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.
[12] J. Schramm,et al. Treatment of Rasmussen encephalitis half a century after its initial description: Promising prospects and a dilemma , 2009, Epilepsy Research.
[13] G. Deuschl,et al. A case of Rasmussen encephalitis treated with rituximab , 2009, Nature Reviews Neurology.
[14] A. Becker,et al. CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. , 2009, Brain : a journal of neurology.
[15] E. Haddad,et al. A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. , 2007, Journal of the American Society of Nephrology : JASN.
[16] C. Elger,et al. Astrocytes are a specific immunological target in Rasmussen's encephalitis , 2007, Annals of neurology.
[17] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[18] C. Elger,et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. , 2005, Brain : a journal of neurology.
[19] Y. Hart. Rasmussen's encephalitis. , 2004, Epileptic disorders : international epilepsy journal with videotape.
[20] J. Cross,et al. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis , 2004, Neurology.
[21] C. Elger,et al. An open study of tacrolimus therapy in Rasmussen encephalitis , 2004, Neurology.
[22] Markus G. Manz,et al. Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice , 2004, Science.
[23] G. Broggi,et al. Experience with immunomodulatory treatments in Rasmussen’s encephalitis , 2003, Neurology.
[24] T. Yednock,et al. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin , 2003, American Journal of Gastroenterology.
[25] R. Spreafico,et al. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures , 2002, Journal of Neuroimmunology.
[26] C. Elger,et al. Destruction of neurons by cytotoxic T cells: A new pathogenic mechanism in rasmussen's encephalitis , 2002, Annals of neurology.
[27] M. Pittet,et al. Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cells. , 2002, Blood.
[28] J. Dichgans,et al. GluR3 antibodies: Prevalence in focal epilepsy but no specificity for Rasmussen’s encephalitis , 2001, Neurology.
[29] J. McNamara,et al. GluR3 Autoantibodies Destroy Neural Cells in a Complement-Dependent Manner Modulated by Complement Regulatory Proteins , 2000, The Journal of Neuroscience.
[30] J. McNamara,et al. Immunoglobulin G and complement immunoreactivity in the cerebral cortex of patients with Rasmussen’s encephalitis , 1999, Neurology.
[31] M. Levite,et al. Autoimmunity to the glutamate receptor in mice--a model for Rasmussen's encephalitis? , 1999, Journal of autoimmunity.
[32] I. Fleidervish,et al. Autoantibodies to the glutamate receptor kill neurons via activation of the receptor ion channel. , 1999, Journal of autoimmunity.
[33] J. Leach,et al. Improvement in adult-onset Rasmussen’s encephalitis with long-term immunomodulatory therapy , 1999, Neurology.
[34] H. Vinters,et al. Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen. , 1997, Journal of immunology.
[35] J. Crawford,et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. , 1996, Blood.
[36] J. McNamara,et al. Plasmapheresis in Rasmussen's encephalitis , 1996, Neurology.
[37] S. Rogers,et al. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site , 1995, Neuron.
[38] H. Otsubo,et al. Chronic encephalitis and epilepsy (Rasmussen's encephalitis) , 1995, Neurology.
[39] J. McNamara,et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. , 1994, Science.
[40] D. Fish,et al. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy) , 1994, Neurology.
[41] C. Benjamin,et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. , 1993, The Journal of clinical investigation.
[42] F. Sánchez‐Madrid,et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. , 1992, Nature.
[43] D. Asher. Virologic studies in chronic encephalitis , 1991 .
[44] J. Girvin,et al. Cytomegalovirus and Rasmussen's encephalitis , 1990, The Lancet.
[45] M. Hammond,et al. Chronic encephalitis, epilepsy, and cerebrovascular immune complex deposits , 1990, Annals of neurology.
[46] G. F. Walter,et al. EPSTEIN-BARR VIRUS IN BRAIN AND RASMUSSEN'S ENCEPHALITIS , 1989, The Lancet.
[47] H. C. Price,et al. ORAL BACTERIAL VACCINE AND COLDS , 1975, The Lancet.
[48] T. Rasmussen,et al. Focal seizures due to chronic localized encephalitis , 1958, Neurology.